SG11201407652RA - Production cell line enhancers - Google Patents
Production cell line enhancersInfo
- Publication number
- SG11201407652RA SG11201407652RA SG11201407652RA SG11201407652RA SG11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new york
- production cell
- edem2
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cell Biology (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181253 A1 (51) International Patent Classification: C07K16/00 (2006.01) C12N15/79 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043116 29 May 2013 (29.05.2013) English English (30) Priority Data: 61/652,549 13/904,587 29 May 2012 (29.05.2012) US 29 May 2013 (29.05.2013) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: CHEN, Gang; 1600 Fox Tail Lane, Yorktown Heights, New York 10598 (US). BURAKOV, Darya; 10 Ashton Road, Yonkers, New York 10705 (US). DESH- PANDE, Dipali; 62 Eldorado Court, White Plains, New York 10603 (US). (74) Agent: JOHNSON, Mary C.; Regeneron Pharmaceutic als, Inc., Ill Old Saw Mill River Road, Tarrytown, New York 10591 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) CJ i-H 00 ^ (54) Title: PRODUCTION CELL LINE ENHANCERS 5 (57) Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the fS yield of useful multi-subunit a protein. Thus, the present invention provides for production cell lines, such as the canonical mam- malian biopharmaceutical production cell - the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed (5T is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1 -encoding polynucleotide. Improved titers S of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261652549P | 2012-05-29 | 2012-05-29 | |
| US13/904,587 US9079954B2 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
| PCT/US2013/043116 WO2013181253A1 (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407652RA true SG11201407652RA (en) | 2014-12-30 |
Family
ID=49670701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606654XA SG10201606654XA (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
| SG11201407652RA SG11201407652RA (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606654XA SG10201606654XA (en) | 2012-05-29 | 2013-05-29 | Production cell line enhancers |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US9079954B2 (en) |
| EP (3) | EP3564262A1 (en) |
| JP (5) | JP6298455B2 (en) |
| KR (4) | KR102663134B1 (en) |
| CN (2) | CN110835624A (en) |
| AU (4) | AU2013267525B2 (en) |
| BR (1) | BR112014029095A2 (en) |
| CA (1) | CA2873131A1 (en) |
| DK (1) | DK2875047T5 (en) |
| EA (2) | EA201792213A1 (en) |
| ES (1) | ES2940900T3 (en) |
| FI (1) | FI2875047T3 (en) |
| HK (1) | HK1205137A1 (en) |
| HU (1) | HUE061479T2 (en) |
| IL (3) | IL235573B (en) |
| MX (1) | MX360359B (en) |
| PL (1) | PL2875047T3 (en) |
| SG (2) | SG10201606654XA (en) |
| TW (2) | TWI641687B (en) |
| WO (1) | WO2013181253A1 (en) |
| ZA (1) | ZA201408289B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI641687B (en) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | Production cell line enhancers |
| CN109071633B (en) | 2016-04-20 | 2022-11-18 | 瑞泽恩制药公司 | Compositions and methods based on the use of expression enhancing loci for the production of antibodies |
| KR102547738B1 (en) | 2016-04-20 | 2023-06-26 | 리제너론 파마슈티칼스 인코포레이티드 | Compositions and methods for making antibodies based on the use of expression enhancing loci |
| US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| US11135266B2 (en) | 2016-11-21 | 2021-10-05 | Just-Evotec Biologics, Inc. | Aflibercept formulations and uses thereof |
| CA3067735A1 (en) | 2017-08-17 | 2019-02-21 | Just Biotherapeutics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60211329T2 (en) | 2001-01-16 | 2007-05-24 | Regeneron Pharmaceuticals, Inc. | ISOLATION OF SEPARATED PROTEINS EXPRESSING CELLS |
| US7455988B2 (en) | 2002-05-29 | 2008-11-25 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| CA2496897C (en) | 2002-08-30 | 2012-01-31 | President And Fellows Of Harvard College | Methods and compositions for modulating xbp-1 activity |
| NZ544335A (en) * | 2003-06-11 | 2009-01-31 | Biogen Idec Inc | Method to increase protein production in culture |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| JP2007537728A (en) * | 2004-03-31 | 2007-12-27 | セントカー・インコーポレーテツド | How to change protein production rate |
| HUE029170T2 (en) * | 2004-07-20 | 2017-03-28 | Genentech Inc | Compositions and methods of using angiopoietin-like 4 protein |
| ES2653843T3 (en) | 2004-09-02 | 2018-02-09 | Wyeth Llc | Protein production systems and procedures |
| JP2008513465A (en) * | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | ER stress reduction in the treatment of obesity and diabetes |
| EP1964922A1 (en) * | 2007-03-02 | 2008-09-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2129685B1 (en) | 2007-03-21 | 2013-11-20 | Danisco US Inc. | Over expression of foldases and chaperones improves protein production |
| ES2522615T3 (en) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP3260129A1 (en) * | 2007-08-03 | 2017-12-27 | Eli Lilly and Company | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
| PE20091163A1 (en) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
| WO2009062789A1 (en) | 2007-11-13 | 2009-05-22 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Improving the secretory capacity in host cells |
| US20090247609A1 (en) * | 2007-12-20 | 2009-10-01 | Hitto Kaufmann | Sm-protein based secretion engineering |
| EP2297331B1 (en) * | 2008-05-28 | 2015-03-25 | Bayer HealthCare, LLC | Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells |
| WO2010008860A1 (en) | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| GB0902180D0 (en) | 2009-02-10 | 2009-03-25 | Ucb Pharma Sa | Method for producing protein |
| US8722046B2 (en) * | 2009-04-08 | 2014-05-13 | The United States Of America As Represented By The Secretary Of The Army | Human monoclonal antibodies protective against bubonic plague |
| DK2438171T3 (en) | 2009-06-02 | 2015-01-26 | Regeneron Pharma | Fucosylerings-deficient cells |
| JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
| JO3274B1 (en) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | Human Antibodies To Human Angiopoietin-Like Protein 4 |
| JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
| TWI641687B (en) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | Production cell line enhancers |
| EP3919069A1 (en) | 2012-11-05 | 2021-12-08 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
-
2013
- 2013-05-28 TW TW102118721A patent/TWI641687B/en active
- 2013-05-28 TW TW107107833A patent/TW201823460A/en unknown
- 2013-05-29 EP EP19177521.2A patent/EP3564262A1/en not_active Withdrawn
- 2013-05-29 HU HUE13729169A patent/HUE061479T2/en unknown
- 2013-05-29 CN CN201911104558.3A patent/CN110835624A/en active Pending
- 2013-05-29 EA EA201792213A patent/EA201792213A1/en unknown
- 2013-05-29 KR KR1020237014681A patent/KR102663134B1/en active IP Right Grant
- 2013-05-29 ES ES13729169T patent/ES2940900T3/en active Active
- 2013-05-29 CN CN201380028164.9A patent/CN104350068B/en active Active
- 2013-05-29 DK DK13729169.6T patent/DK2875047T5/en active
- 2013-05-29 US US13/904,587 patent/US9079954B2/en active Active
- 2013-05-29 WO PCT/US2013/043116 patent/WO2013181253A1/en active Application Filing
- 2013-05-29 FI FIEP13729169.6T patent/FI2875047T3/en active
- 2013-05-29 CA CA2873131A patent/CA2873131A1/en active Pending
- 2013-05-29 EA EA201492242A patent/EA028790B1/en not_active IP Right Cessation
- 2013-05-29 SG SG10201606654XA patent/SG10201606654XA/en unknown
- 2013-05-29 PL PL13729169.6T patent/PL2875047T3/en unknown
- 2013-05-29 AU AU2013267525A patent/AU2013267525B2/en active Active
- 2013-05-29 MX MX2014014630A patent/MX360359B/en active IP Right Grant
- 2013-05-29 KR KR1020147033930A patent/KR102126210B1/en active IP Right Grant
- 2013-05-29 KR KR1020217043208A patent/KR102528950B1/en active IP Right Grant
- 2013-05-29 JP JP2015515154A patent/JP6298455B2/en active Active
- 2013-05-29 KR KR1020207017417A patent/KR102346867B1/en active IP Right Grant
- 2013-05-29 EP EP22214230.9A patent/EP4219546A3/en active Pending
- 2013-05-29 BR BR112014029095A patent/BR112014029095A2/en not_active Application Discontinuation
- 2013-05-29 EP EP13729169.6A patent/EP2875047B1/en active Active
- 2013-05-29 SG SG11201407652RA patent/SG11201407652RA/en unknown
-
2014
- 2014-11-09 IL IL235573A patent/IL235573B/en active IP Right Grant
- 2014-11-12 ZA ZA2014/08289A patent/ZA201408289B/en unknown
- 2014-11-26 US US14/555,220 patent/US9382315B2/en active Active
-
2015
- 2015-06-11 US US14/737,090 patent/US10227401B2/en active Active
- 2015-06-12 HK HK15105590.6A patent/HK1205137A1/en unknown
- 2015-06-29 US US14/754,112 patent/US9193786B2/en active Active
- 2015-06-29 US US14/754,146 patent/US9228012B2/en active Active
-
2016
- 2016-07-01 US US15/201,104 patent/US9688751B2/en not_active Ceased
-
2017
- 2017-06-16 US US15/624,982 patent/US10351622B2/en active Active
-
2018
- 2018-02-14 AU AU2018201094A patent/AU2018201094B2/en active Active
- 2018-02-23 JP JP2018030324A patent/JP6622334B2/en active Active
-
2019
- 2019-04-07 IL IL265867A patent/IL265867A/en unknown
- 2019-04-17 US US16/387,134 patent/USRE48651E1/en active Active
- 2019-05-21 US US16/417,792 patent/US10611831B2/en active Active
- 2019-05-30 AU AU2019203780A patent/AU2019203780B2/en active Active
- 2019-11-21 JP JP2019210124A patent/JP7037535B2/en active Active
-
2021
- 2021-01-03 IL IL279922A patent/IL279922A/en unknown
- 2021-10-01 AU AU2021240303A patent/AU2021240303A1/en active Pending
- 2021-12-27 JP JP2021212131A patent/JP7382383B2/en active Active
-
2023
- 2023-08-22 JP JP2023134346A patent/JP2023153268A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201407652RA (en) | Production cell line enhancers | |
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201804400SA (en) | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201407774XA (en) | Conversion of biomass | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201808398PA (en) | Cell line for recombinant protein and/or viral vector production | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201407472SA (en) | Motion compensation and motion estimation leveraging a continuous coordinate system | |
| SG11201804712PA (en) | Biofuel | |
| SG11201407505XA (en) | Aptamer-based multiplexed assays |